A Preliminary Study to Evaluate the Immune Response to a Booster Dose of the Adult Tetanus-Diphtheria Vaccine (Td) Available in Iran Publisher



Noorian S¹ ; Mottaghidastjerdi N¹ ; Soltanyrezaeerad M² ; Montazeri H¹ ; Baghaei M^{2, 3} ; Niazi MJ^{1, 4}
Source: Iranian Journal of Pharmaceutical Research Published:2024

Abstract

Background: Despite the availability of tetanus-diphtheria (TD) vaccines in Iran, the seroconversion rate of these products as a booster dose is unknown. Objectives: This study evaluates the seroconversion rate of the Iranian Td vaccine in adults who have not been vaccinated in the past decade. Methods: In this study, 20 adult volunteers aged 18 to 60 who had not received the Td vaccine in the past decade received a booster dose of the Iranian Td vaccine. Twenty-eight days after vaccination, the seroconversion rate was evaluated using the ELISA method. Vaccine adverse events were monitored at three time points after vaccination. Results: Seroconversion rates with the Iranian Td vaccine boosters were 75% and 90%, respectively, based on a 4-fold increase in anti-tetanus toxoid antibody titers and a 2- and 4-fold combination. Significant associations were found between the demographic data, specifically female gender and age 43 years and older, with seroconversion rates. Injection-site pain was the most common adverse reaction, with a frequency of 35%. No adverse events were reported between one week and one month after vaccination. Conclusions: Results showed that a booster dose of the Iranian Td vaccine produced a protective titer (> 0.1 ILI/mL) and a longterm protective titer (> 1.0 IlJ/mL) in 100% of participants. The seroconversion rate of the Iranian Td vaccine was comparable to other common tetanus vaccines, including Tenivac®, Adacel®, Infanrix®, Tetavax®, and Vacteta®. The proportion of suitable candidates for plasma donation, based on minimum (2 IlJ/mL) and maximum (10 ILI/mL) anti-tetanus toxoid antibody titers, was 100% and 45%, respectively. © 2024, Noorian et al.